AVATAR

avatar-logo

Ace inhibition for the preservation of renal function and patient survival in kidney transplantation. Local (ANZ) title: Ace inhibitors Versus plAcebo Therapy After Renal transplantation

Principal Investigator: Dr Greg Knoll, Ottawa Hospital Research Institute
Local (ANZ) Principal Investigator: Dr Helen Pilmore, Auckland City Hospital, NZ
Project Officer: Donna Reidlinger (AKTN)

The AVATAR trial  is a multi-centre, double-blind, randomised controlled trial comparing the ACE inhibitor ramipril to placebo in 528 renal transplant recipients with chronic kidney disease defined by reduced glomerular filtration rate and the presence of proteinura. The trial is designed to determine if ramipril is superior to placebo in decreasing the time to doubling of serum creatine or renal transplant failure (defined as return to dialysis or repeat transplantation) or death.

Renal transplant recipients who: a) have an estimated glomerular filtration rate >20ml/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD) study equation which has been validated in renal transplant patients; b) have proteinuria ≥0.2 grams/day; c) are at least three months post-transplantation; d) have signed informed consent will be randomised to receive Ramipril (10mg daily) or matched placebo.

This trial is being led by Dr Greg Knoll through Ottawa Hospital Research Institute in Canada. The AKTN is facilitating the Australian and New Zealand arm of the trial. 528 patients will be randomised across all sites, and followed from between 2 and 4 years.

Contact Donna Reidlinger for more information.